TLR4 and cancer: The agonist of this gene has been a matter of many studies focused on cancer immunotherapy, and nowadays, FDA approval for clinical application in cancer treatment has been obtained for two TLR4 ligands, Bacillus Calmette-Guérin and monophosphoryl lipid A [68,69].